Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Ultragenyx Pharmaceutical (RARE) Receivables - Net (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Receivables - Net for 10 consecutive years, with $158.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 29.51% to $158.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $158.0 million, a 29.51% increase, with the full-year FY2025 number at $158.0 million, up 29.51% from a year prior.
  • Receivables - Net was $158.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $112.5 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $158.0 million in Q4 2025 to a low of $24.7 million in Q2 2021.
  • A 5-year average of $71.1 million and a median of $72.0 million in 2023 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: fell 14.65% in 2021, then surged 154.34% in 2023.
  • Ultragenyx Pharmaceutical's Receivables - Net stood at $28.4 million in 2021, then soared by 42.25% to $40.4 million in 2022, then skyrocketed by 81.46% to $73.4 million in 2023, then surged by 66.24% to $122.0 million in 2024, then grew by 29.51% to $158.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Receivables - Net are $158.0 million (Q4 2025), $112.5 million (Q3 2025), and $124.5 million (Q2 2025).